NCT02015754View on ClinicalTrials.gov

Irinotecan -Eluting LC Bead-M1 (DEBIRI-M1) for Patients With Liver Metastases From Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

June 2, 2015

Study Completion Date

December 13, 2016

Conditions
Colorectal Cancer
Interventions
DRUG

DEBIRI

Irinotecan hydrochloride is a semisynthetic derivative of camptothecin, an alkaloid extracted from the tree Camptotheca acuminata. Irinotecan hydrochloride trihydrate is a pale yellow to yellow crystalline powder, it is mixed in DC Beads and injected in the tumor.

DEVICE

LC Bead M1

The LC Bead M1, loaded with irinotecan (DEBIRI-M1) to treat patients with hepatic metastases from colorectal cancer.

PROCEDURE

TACE

TACE a minimally invasive procedure performed to restrict a tumor's blood supply.

Trial Locations (1)

21287

The Johns Hopkins Hospital, Baltimore

All Listed Sponsors
lead

Yale University

OTHER

NCT02015754 - Irinotecan -Eluting LC Bead-M1 (DEBIRI-M1) for Patients With Liver Metastases From Colorectal Cancer | Biotech Hunter | Biotech Hunter